The University of North Carolina AIDS Clinical Trials Unit (ACTU) is dedicated to developing and conducting research of HIV prevention, HIV disease, HIV associated opportunistic infections, and complications of HIV therapy. The UNC ACTU provides access to promising clinical trials to individuals living in and around North Carolina and at our partner sites outside the U.S.
Established and continuously funded since 1987, UNC is one of the most successful ACTUs in the country, providing access to a variety of studies including investigations of antiretroviral therapies, immune modulators, treatments of opportunistic infections and HIV-related malignancies, neurologic complications and viral co-infections. (View open studies)
In 2007, the mission of the unit was expanded to include HIV prevention vaccine trials in collaboration with the international organization HIV Vaccine Trials Network (HVTN). The UNC Vaccine Trials Unit (VTU) is dedicated to the fight against HIV/AIDS in the HIV-uninfected community. In furtherance of this mission, the VTU will work to increase community awareness regarding the role of HIV preventative vaccines as the world's best hope to stop AIDS and evaluating vaccines in development through clinical trials. (More vaccine trials)
The UNC ACTU and VTU are committed to community outreach, continuing education and consultation for health care providers and providing training for other domestic and international HIV/AIDS research units. As we enter the third decade of the HIV epidemic, the UNC ACTU remains committed to the prevention of HIV disease and the continuing search for effective and safe therapies for HIV infection.